Skip to Content
Merck

Key Documents

View All Documentation

Skip To

74817

FITC-CM-Dextran

average mol wt 150,000

Synonym(s):

FITC-CM-Dextran 150, Fluorescein isothiocyanate–Carboxymethyl–Dextran

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

NACRES:
NA.32
UNSPSC Code:
12352108
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

synthetic

Quality Level

100

conjugate

FITC conjugate

form

powder or crystals

mol wt

average mol wt 150,000

composition

carboxymethyl content, 3-7%

extent of labeling

0.001-0.020 mol FITCmol glucose

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

General description

FITC-CM-Dextran, also known as Fluorescein isothiocyanate–Carboxymethyl–Dextran, is an anionic fluorescent probe. The carboxyl group provides the negative charge, which improves the overall permeability of the molecule. It is supplied as a yellow powder that is freely soluble in water and electrolyte solutions. FITC-CM-Dextran is insoluble in most organic samples such as ethanol, methanol, acetone, and chloroform.

FITC-CM-Dextran is manufactured by reacting selected dextran fractions with an activated carboxymethyl derivative in alkali, whereby O-carboxymethyl groups are introduced along the dextran chain.

Application

FITC-CM-dextran is used to study drug intake and delivery mechanisms in HeLa cell lines. FITC-CM-Dextran was chosen due to its high water solubility and negative charge.[1]

It is also a suitable molecule to be used in encapsulation studies for polymersomal drug delivery systems or Ps DDS[2] . FITC-CM-Dextran is a biocompatible molecule used as a starting material in several pharmaceutical and diagnostic applications.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
680595347153379
Sigma-Aldrich

Sigma-Aldrich

74817

FITC-CM-Dextran

Sigma-Aldrich

Sigma-Aldrich

68059

FITC-CM-Dextran

Sigma-Aldrich

Sigma-Aldrich

53471

FITC-CM-Dextran

Sigma-Aldrich

Sigma-Aldrich

53379

FITC-CM-Dextran

biological source

synthetic

biological source

synthetic

biological source

-

biological source

synthetic

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

form

powder or crystals

form

powder or crystals

form

powder or crystals

form

powder or crystals

composition

carboxymethyl content, 3-7%

composition

carboxymethyl content, 3-7%

composition

carboxymethyl content, 3-7%

composition

carboxymethyl content, 3-7%

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

fluorescence

λex 493 nm; λem 517 nm±5 nm in 0.1 M Tris pH 8.0

mol wt

average mol wt 150,000

mol wt

average mol wt 4,000

mol wt

average mol wt 70,000

mol wt

average mol wt 40,000

Still not finding the right product?

Explore all of our products under FITC-CM-Dextran

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCP5190
BCCL5925
BCCJ8826
BCCH0189
BCCG4070

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marco Romano et al.
Oncoimmunology, 6(10), e1345402-e1345402 (2017-11-11)
Myelofibrosis (MF) is a clonal neoplasia associated with chronic inflammation due to aberrant cytokine production. Mutations in Janus Kinase-2 (JAK2), calreticulin (CALR) and myeloproliferative leukemia protein (MPL) genes have been recently associated to MF and they all activate the JAK/STAT
Chloe Martin et al.
International journal of pharmaceutics, 511(1), 570-578 (2016-07-28)
The need to develop a greater understanding of drug delivery systems has arisen through the development of alternative biological based therapeutics. Drug delivery systems need to adapt and respond to this increasing demand for cellular transportation of highly charged species.
Chloe Martin et al.
International journal of pharmaceutics, 481(1-2), 1-8 (2015-01-17)
The field of therapeutics is evolving to include a greater proportion of higher molecular weight, hydrophilic biological compounds. To cater for this new era in healthcare the concomitant development of appropriate drug delivery systems is essential to aid cellular permeation.

Global Trade Item Number

SKUGTIN
74817-1G04061823356183

Questions

Reviews

No rating value

Active Filters